gsk201201166k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending January 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 



Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
 
 
This announcement supplements the announcements released on 7 October 2011 at 18.10  and 11 July 2011 at 18.01.
 
The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the "Plan") notified the Company and the under-mentioned persons on 7 October 2011 and on 11 July 2011 of an increase in their notional interests in Ordinary shares and ADRs following the reinvestment of dividends paid to shareholders on 6 October 2011 and 7 July 2011 respectively.
 
 
 
 
 
 PDMR
 
 
 
             Number of Ordinary shares acquired
             on 7th July 2011 at a price of 1359.50
             pence per Ordinary share
 
 
 
        Number of Ordinary shares acquired
        on 6th October 2011 at a price of
        1345 pence per Ordinary share
 
 
    Personal
    Element
 
    Matching
    Element
 
    Personal
    Element
 
    Matching
    Element
 
Sir Andrew Witty
 
                      
301
 
301
 
308
 
308
 
Mr S M Bicknell
 
 
79
 
79
 
-
 
                        -
 
Mr D S Redfern
 
 
89
 
89
 
-
 
        -
 
Ms C Thomas
 
 
19
 
19
 
-
 
        -
 
Dr P J T Vallance
 
 
177
 
177
 
  -
 
        -
 
 
            Number of ADRs acquired on 7th
            July 2011 at a price of $43.59 per ADR
 
       Number of ADRs acquired on 6th
       October 2011 at a price of $41.83 per ADR
 
 
    Personal
    Element
 
    Matching
    Element
 
    Personal
    Element
 
    Matching
    Element
 
Mrs D P Connelly
 
 
    45
 
    45
 
-
 
-
 
Dr M M Slaoui
 
 
    226
 
    226
 
-
 
-
 
Mr D E Troy
 
    113
 
   113
 
-
 
-
           
 
 
   
The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant three year measurement period.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
 
V A Whyte
Company Secretary
 
16 January 2012
 
 
 

 


 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: January 16, 2012
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc